thiosulfates has been researched along with Kidney Diseases in 46 studies
Thiosulfates: Inorganic salts of thiosulfuric acid possessing the general formula R2S2O3.
thiosulfate(2-) : A divalent inorganic anion obtained by removal of both protons from thiosulfuric acid.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
Excerpt | Relevance | Reference |
---|---|---|
"To evaluate the effect of sodium thiosulfate (STS) on cisplatin clearance after transcatheter embolization (TAE) with a lipiodol-platinum suspension (LPS) in patients with hepatocellular carcinoma (HCC)." | 9.14 | Effect of sodium thiosulfate on cisplatin removal after intra-arterial embolization with a lipiodol-platinum suspension for hepatocellular carcinoma. ( Ikeda, O; Iryo, Y; Nakasone, Y; Tamura, Y; Yamashita, Y, 2010) |
"Calciphylaxis is associated with medial arteriolar vascular calcification and results in ischemic subcutaneous necrosis with vulnerable skin ulcerations and high mortality." | 6.43 | Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. ( Hayden, MR; Khanna, R; Kolb, L; Sowers, JR; Tyagi, SC, 2005) |
"To evaluate the effect of sodium thiosulfate (STS) on cisplatin clearance after transcatheter embolization (TAE) with a lipiodol-platinum suspension (LPS) in patients with hepatocellular carcinoma (HCC)." | 5.14 | Effect of sodium thiosulfate on cisplatin removal after intra-arterial embolization with a lipiodol-platinum suspension for hepatocellular carcinoma. ( Ikeda, O; Iryo, Y; Nakasone, Y; Tamura, Y; Yamashita, Y, 2010) |
" After oral application, only 4% of STS was recovered in urine of volunteers, reflecting a low bioavailability of 7." | 2.76 | Sodium thiosulfate pharmacokinetics in hemodialysis patients and healthy volunteers. ( Farese, S; Frey, BM; Frey, FJ; Hildebrandt, T; Kalicki, R; Pasch, A; Stauffer, E; Uehlinger, DE, 2011) |
"Calciphylaxis is associated with medial arteriolar vascular calcification and results in ischemic subcutaneous necrosis with vulnerable skin ulcerations and high mortality." | 2.43 | Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. ( Hayden, MR; Khanna, R; Kolb, L; Sowers, JR; Tyagi, SC, 2005) |
"Nephrotoxicity is a relatively common and potentially serious adverse effect of treatment with certain cytotoxic drugs (especially ifosfamide)." | 2.39 | Strategies to prevent nephrotoxicity of anticancer drugs. ( Skinner, R, 1995) |
"Cisplatin is a nephrotoxic drug; however, agents that may make cisplatin therapy more safe and rewarding will be available in the near future." | 2.38 | Newer insights into cisplatin nephrotoxicity. ( Anand, AJ; Bashey, B, 1993) |
"Renal dysfunction and urinary disorders are the most troublesome adverse reaction to anticancer agents such as cisplatin (CDDP) and ifosfamide (IFM)." | 2.38 | [New treatments for urogenital toxicity of anti-neoplastic chemotherapy]. ( Hirosawa, A; Niitani, H; Shibuya, M, 1990) |
" Therapeutic strategies aimed at reducing toxicity and allowing dose escalation of intravenous cisplatin, such as administration in hypertonic saline and pharmacokinetically based dosing schedules, have been partially successful in reducing nephrotoxicity and bone marrow suppression." | 2.38 | Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate. ( DeGregorio, MW; Gandara, DR; Makuch, RW; Perez, EA; Wiebe, VJ, 1990) |
"ESRD was secondary to nephronophthisis (n = 1), membranoproliferative glomerulonephritis (n = 1), diabetic nephropathy (n = 1), and thrombotic microangiopathy (n = 1)." | 1.40 | Sodium thiosulphate treatment of uraemic tumoral calcinosis. ( Bardin, T; Cohen-Solal, M; Ea, HK; Lioté, F; Malbos, S; Trout, H; Urena-Torres, P, 2014) |
"Sodium thiosulfate treatment transiently lowered plasma ionized calcium and induced metabolic acidosis." | 1.35 | Sodium thiosulfate prevents vascular calcifications in uremic rats. ( Farese, S; Frey, BM; Frey, FJ; Huynh-Do, U; Pasch, A; Schaffner, T, 2008) |
"Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage." | 1.27 | High-dose cisplatin with sodium thiosulfate protection. ( Andrews, PA; Felthouse, RD; Howell, SB; Markman, M; Murphy, MP; Pfeifle, CE; Woliver, TB, 1985) |
"Sodium thiosulfate was shown to protect renal function, as well as lessen hematologic complications of cisplatin therapy." | 1.27 | Experimental and clinical results with intraperitoneal cisplatin. ( Aartsen, E; Dubbelman, R; Franklin, H; McVie, JG; ten Bokkel Huinink, WW, 1985) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 19 (41.30) | 18.7374 |
1990's | 12 (26.09) | 18.2507 |
2000's | 10 (21.74) | 29.6817 |
2010's | 5 (10.87) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Nigwekar, SU | 1 |
Thadhani, R | 1 |
Brandenburg, VM | 1 |
Malbos, S | 1 |
Urena-Torres, P | 1 |
Cohen-Solal, M | 1 |
Trout, H | 1 |
Lioté, F | 1 |
Bardin, T | 1 |
Ea, HK | 1 |
Pasch, A | 2 |
Schaffner, T | 1 |
Huynh-Do, U | 1 |
Frey, BM | 2 |
Frey, FJ | 2 |
Farese, S | 2 |
Rogers, NM | 1 |
Coates, PT | 1 |
O'Neill, WC | 2 |
Tamura, Y | 1 |
Ikeda, O | 1 |
Nakasone, Y | 1 |
Iryo, Y | 1 |
Yamashita, Y | 1 |
Lomashvili, KA | 1 |
Stauffer, E | 1 |
Kalicki, R | 1 |
Hildebrandt, T | 1 |
Uehlinger, DE | 1 |
Leitao, DJ | 1 |
Blakley, BW | 2 |
CASTEX, MR | 1 |
ESPOSITO, S | 1 |
BLAGMAN, GF | 1 |
ESTRIN, EI | 1 |
DVORKINA, EB | 1 |
MINTS, OI | 1 |
Hayden, MR | 2 |
Tyagi, SC | 1 |
Kolb, L | 1 |
Sowers, JR | 1 |
Khanna, R | 1 |
Viallet, NR | 1 |
Begleiter, A | 1 |
Leith, MK | 1 |
Meissner, M | 1 |
Kaufmann, R | 1 |
Gille, J | 1 |
Ackermann, F | 1 |
Levy, A | 1 |
Daugas, E | 1 |
Schartz, N | 1 |
Riaux, A | 1 |
Derancourt, C | 1 |
Urena, P | 1 |
Lebbé, C | 1 |
Skinner, R | 1 |
Nagai, N | 1 |
Hotta, K | 1 |
Yamamura, H | 1 |
Ogata, H | 1 |
Guastalla, JP | 1 |
Vermorken, JB | 1 |
Wils, JA | 1 |
George, M | 1 |
Scotto, V | 1 |
Nooij, M | 1 |
ten Bokkel Huinnink, WW | 1 |
Dalesio, O | 1 |
Renard, J | 1 |
Anand, AJ | 1 |
Bashey, B | 1 |
Kim, S | 1 |
Howell, SB | 3 |
McClay, E | 1 |
Kirmani, S | 1 |
Goel, R | 1 |
Plaxe, S | 1 |
Braly, P | 1 |
Bonetti, A | 1 |
Miki, Y | 1 |
Iwase, K | 1 |
Kamiike, W | 1 |
Taniguchi, E | 1 |
Sakaguchi, K | 1 |
Sumimura, J | 1 |
Matsuda, H | 1 |
Nagai, I | 1 |
Kazama, JJ | 1 |
Kutsuwada, K | 1 |
Ataka, K | 1 |
Maruyama, H | 1 |
Gejyo, F | 1 |
Bailey, K | 1 |
Chow, AY | 1 |
Downie, RH | 1 |
Pike, RK | 1 |
Reichman, B | 1 |
Markman, M | 3 |
Hakes, T | 1 |
Budnick, A | 1 |
Rubin, S | 1 |
Jones, W | 1 |
Almadrones, L | 1 |
Lewis, JL | 1 |
Hoskins, W | 1 |
Brillet, G | 1 |
Deray, G | 1 |
Bunker, D | 1 |
Ben Hmida, M | 1 |
Baumelou, A | 1 |
Jacobs, C | 1 |
Shibuya, M | 1 |
Hirosawa, A | 2 |
Niitani, H | 2 |
Tognella, S | 1 |
Gandara, DR | 1 |
Wiebe, VJ | 1 |
Perez, EA | 1 |
Makuch, RW | 1 |
DeGregorio, MW | 1 |
Saito, D | 1 |
Fujii, T | 1 |
Yoshida, S | 1 |
Ohkura, H | 1 |
Oguro, Y | 1 |
Nagase, S | 1 |
Narita, M | 1 |
Aamdal, S | 1 |
Fodstad, O | 1 |
Pihl, A | 1 |
Sakai, S | 1 |
Iizuka, K | 1 |
Hayashibara, K | 1 |
Tsuboi, E | 1 |
Cleary, S | 1 |
De Broe, ME | 1 |
Wedeen, RP | 1 |
Pfeifle, CE | 1 |
Felthouse, RD | 1 |
Woliver, TB | 1 |
Andrews, PA | 1 |
Murphy, MP | 1 |
ten Bokkel Huinink, WW | 1 |
Dubbelman, R | 1 |
Aartsen, E | 1 |
Franklin, H | 1 |
McVie, JG | 1 |
Ito, T | 1 |
Niwa, T | 1 |
Matsui, E | 1 |
Hosain, F | 2 |
Wagner, HN | 2 |
Vorburger, C | 1 |
Riedwyl, H | 1 |
Reubi, F | 2 |
Francois, B | 1 |
Pozet, N | 1 |
Rattanachane, B | 1 |
Traeger, J | 1 |
James, AE | 1 |
DeLand, FH | 1 |
Reba, RC | 1 |
Anghel, S | 1 |
Jahnecke, J | 1 |
Sökeland, J | 1 |
Schmidt, AW | 1 |
Krück, F | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Effects of Human Amniotic Mesenchymal Stem Cells (hAMSCs) on Wound Healing in Uremic Calciphylaxis Patients: an Open Label Single Arm Study[NCT04592640] | 7 participants (Anticipated) | Interventional | 2018-09-17 | Active, not recruiting | |||
The Pharmacologic Profile of Sodium Thiosulfate in Renal Failure and Healthy[NCT01008631] | 19 participants (Actual) | Interventional | 2009-09-30 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
13 reviews available for thiosulfates and Kidney Diseases
Article | Year |
---|---|
Calciphylaxis.
Topics: Age of Onset; Calciphylaxis; Debridement; Diagnosis, Differential; Humans; Kidney Diseases; Microves | 2018 |
Calcific uraemic arteriolopathy: an update.
Topics: Calciphylaxis; Calcium; Chelating Agents; Chronic Disease; Humans; Hyperbaric Oxygenation; Kidney Di | 2008 |
Treatment of vascular calcification.
Topics: Animals; Calcinosis; Humans; Kidney Diseases; Renal Circulation; Thiosulfates; Vascular Diseases | 2008 |
Recent progress in the treatment of vascular calcification.
Topics: Animals; Calcinosis; Diphosphonates; Disease Models, Animal; Humans; Kidney Diseases; Thiosulfates; | 2010 |
Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate.
Topics: Animals; Antioxidants; Arteries; Atherosclerosis; Calcinosis; Calciphylaxis; Chelating Agents; Chron | 2005 |
Strategies to prevent nephrotoxicity of anticancer drugs.
Topics: Adult; Antineoplastic Agents; Cell Line; Chelating Agents; Child; Child, Preschool; Cisplatin; Human | 1995 |
Newer insights into cisplatin nephrotoxicity.
Topics: Amifostine; Animals; Cisplatin; Furosemide; Glutathione; Humans; Kidney Diseases; Male; Mannitol; So | 1993 |
[Can cisplatin renal toxicity be prevented?].
Topics: Calcium Channel Blockers; Cisplatin; Diuretics; Humans; Kidney Diseases; Neoplasms; Thiosulfates | 1991 |
[New treatments for urogenital toxicity of anti-neoplastic chemotherapy].
Topics: Antidotes; Antineoplastic Agents; Cisplatin; Humans; Ifosfamide; Kidney Diseases; Mesna; Thiosulfate | 1990 |
Pharmacological interventions to reduce platinum-induced toxicity.
Topics: Adrenocorticotropic Hormone; Amifostine; Cisplatin; Ditiocarb; Fluid Therapy; Glutathione; Hematolog | 1990 |
Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate.
Topics: Amifostine; Antidotes; Cisplatin; Ditiocarb; Drug Therapy, Combination; Humans; Kidney Diseases; Thi | 1990 |
[Effect of sodium thiosulfate on the anti-tumor effect and nephrotoxicity of CDDP in human gastric cancer].
Topics: Antidotes; Cisplatin; Humans; Kidney Diseases; Stomach Neoplasms; Thiosulfates | 1990 |
Some procedures to reduce cis-platinum toxicity reduce antitumour activity.
Topics: Animals; Cisplatin; Kidney Diseases; Mice; Neoplasms, Experimental; Saline Solution, Hypertonic; Sod | 1987 |
7 trials available for thiosulfates and Kidney Diseases
Article | Year |
---|---|
Effect of sodium thiosulfate on cisplatin removal after intra-arterial embolization with a lipiodol-platinum suspension for hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chelating Agents; Chemoem | 2010 |
Sodium thiosulfate pharmacokinetics in hemodialysis patients and healthy volunteers.
Topics: Administration, Oral; Adult; Aged; Biological Availability; Biotransformation; Cardiovascular Agents | 2011 |
Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy--a phase II study of the EORTC Gynaecological Cancer Cooperative Grou
Topics: Aged; Catheterization, Peripheral; Cisplatin; Female; Humans; Infusions, Parenteral; Kidney Diseases | 1994 |
Dose intensification of cisplatin chemotherapy through biweekly administration.
Topics: Adult; Aged; Bone Marrow Diseases; Cisplatin; Drug Administration Schedule; Female; Hearing Disorder | 1993 |
Serum cystatin C reliably detects renal dysfunction in patients with various renal diseases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Creatine; Cystatin C; Cystatins; Female; Glo | 2002 |
Phase II trial of high-dose cisplatin with sodium thiosulfate nephroprotection in patients with advanced carcinoma of the uterine cervix previously untreated with chemotherapy.
Topics: Adult; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Evaluation; Female; Hearing Diso | 1991 |
[Combination effects of cis-dichlorodiammineplatinum (II) and sodium thiosulfate on renal dysfunction].
Topics: Blood Urea Nitrogen; Cisplatin; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration | 1987 |
26 other studies available for thiosulfates and Kidney Diseases
Article | Year |
---|---|
Sodium thiosulphate treatment of uraemic tumoral calcinosis.
Topics: Aged; Calcinosis; Comorbidity; Female; Humans; Hypertension; Incidence; Kidney Diseases; Kidney Fail | 2014 |
Sodium thiosulfate prevents vascular calcifications in uremic rats.
Topics: Animals; Aortic Diseases; Bone and Bones; Calcinosis; Calcium; Kidney Diseases; Rats; Renal Circulat | 2008 |
Quantification of sodium thiosulphate protection on cisplatin-induced toxicities.
Topics: Animals; Antidotes; Antineoplastic Agents; Cisplatin; Disease Models, Animal; Dose-Response Relation | 2003 |
[Sodium thiosulfate & sodium hyposulfite in liver & kidney diseases].
Topics: Dithionite; Humans; Kidney; Kidney Diseases; Liver Diseases; Sodium; Sulfites; Thiosulfates | 1958 |
[The urinary elimination of the dextran molecule as index of glomerular permeability. Relation between the clearance of dextran and the clearance of sodium hyposulfite].
Topics: Dextrans; Dithionite; Humans; Kidney Diseases; Kidney Function Tests; Kidney Glomerulus; Permeabilit | 1959 |
[Determination of renal filtration with the aid of thiosulfate and the maximum glomerular reabsorption of glucose].
Topics: Glucose; Humans; Kidney; Kidney Diseases; Thiosulfates | 1951 |
Effect of sodium thiosulphate and cis-diamminedichloroplatinum on FADU tumour cells in nude mice.
Topics: Animals; Antineoplastic Agents; Antioxidants; Carcinoma, Squamous Cell; Cisplatin; Disease Models, A | 2005 |
Sodium thiosulphate: a new way of treatment for calciphylaxis?
Topics: Antioxidants; Calciphylaxis; Chelating Agents; Humans; Kidney Diseases; Thiosulfates | 2007 |
Sodium thiosulfate as first-line treatment for calciphylaxis.
Topics: Calciphylaxis; Diabetes Complications; Female; Humans; Kidney Diseases; Kidney Transplantation; Leg | 2007 |
Calciphylaxis and the cardiometabolic syndrome: the emerging role of sodium thiosulfate as a novel treatment option.
Topics: Antioxidants; Arteries; Calciphylaxis; Humans; Kidney Diseases; Metabolic Syndrome; Renal Dialysis; | 2008 |
Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.
Topics: Analysis of Variance; Animals; Cisplatin; Glomerular Filtration Rate; Kidney; Kidney Diseases; Male; | 1995 |
Laparoscopic cholecystectomy and time-course changes in renal function. The effect of the retraction method on renal function.
Topics: Adult; Cholecystectomy, Laparoscopic; Female; Glomerular Filtration Rate; Hemodynamics; Humans; Kidn | 1997 |
1-Piperidinocyclohexanecarbonitrile, a toxic precursor of phencyclidine.
Topics: Animals; Chemical and Drug Induced Liver Injury; Kidney Diseases; Lethal Dose 50; Male; Mice; Nitril | 1976 |
[Clinical significance of the sodium thiosulfate clearance test].
Topics: Female; Glomerular Filtration Rate; Humans; Kidney Diseases; Male; Pregnancy; Reference Values; Thio | 1989 |
Hypomagnesemia following high-dose intracavitary cisplatin with systemically administered sodium thiosulfate.
Topics: Adult; Aged; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Kidney Diseases | 1986 |
Prevention of cisplatin nephrotoxicity.
Topics: Cisplatin; Humans; Kidney Diseases; Thiosulfates | 1986 |
High-dose cisplatin with sodium thiosulfate protection.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Interaction | 1985 |
Experimental and clinical results with intraperitoneal cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheterization; Catheters, Indwelling; Cisplatin; F | 1985 |
Fibrinolytic activity in renal disease.
Topics: Cholesterol; Chronic Disease; Creatinine; Female; Fibrinogen; Fibrinolysin; Fibrinolysis; Glomerulon | 1972 |
Measurement of extracellular fluid volume with 169Yb-diethylenetriaminepentaacetate.
Topics: Animals; Carbon Isotopes; Dogs; Extracellular Space; Half-Life; Humans; Inulin; Kidney Diseases; Met | 1971 |
[Comparative studies on the renal clearance of Na-Cr2Cr51 ethylenediaminetetraacetate, inulin and sodium thiosulfate in humans].
Topics: Chromium Isotopes; Edetic Acid; Glomerular Filtration Rate; Humans; Inulin; Kidney; Kidney Diseases; | 1969 |
[Estimation of glomerular filtration using 51 Cr E.D.T.A].
Topics: Adolescent; Adult; Chromium Isotopes; Edetic Acid; Female; Glomerular Filtration Rate; Humans; Kidne | 1971 |
169 Ytterbium diethylenetriaminepentaacetic acid ( 169 YB DTPA)--a versatile radiopharmaceutical.
Topics: Body Weight; Brain Diseases; Extracellular Space; Glomerular Filtration Rate; Humans; Injections, In | 1971 |
[Current methods of study in determination of renal clearances with saluresis and waterdiuresis].
Topics: Aminohippuric Acids; Blood Flow Velocity; Diuresis; Glomerular Filtration Rate; Humans; Hypertension | 1970 |
[Blood levels, excretion and dosage of N-pyrrolidino-methyl-tetracycline (PMT, Reverin) in kidney patients].
Topics: Creatine; Creatinine; Glomerular Filtration Rate; Humans; Injections, Intravenous; Inulin; Kidney; K | 1967 |
Stop-flow analysis in man.
Topics: Aminohippuric Acids; Chlorides; Female; Furosemide; Humans; Inulin; Kidney Diseases; Kidney Function | 1966 |